CBD absorption from formulations containing TPM was compared against a commonly prescribed CBD product comprising CBD at 100 mg/ml.
All TPM formulations produced higher mean AUC and Cmax than the commercial CBD formulation.
- Increases in AUC produced by TPM® formulations ranged from ~4-40 times
- Increases in Cmax produced by TPM® formulations ranged from ~6-41 times
- These increases were statistically significant for the best performing TPM® formulations
The only commonly prescribed pure CBD product which is also FDA and EMA approved is GW Pharma’s Epidiolex (it also received TGA approval last month).
Epidiolex is an oral solution at 100mg/mL. It incorporates sesame seed oil as a lipid solvent.
Epidiolex was launched in the US just under two years ago. The company reported just under US$300 m in sales in its first year on the market.
https://reference.medscape.com/drug/epidiolex-cannabidiol-1000225
https://ir.gwpharm.com/news-release...-plc-reports-fourth-quarter-and-year-end-2019
- Forums
- ASX - By Stock
- AVE
- Ann: TPM Cannabinoid Development Program Update
Ann: TPM Cannabinoid Development Program Update, page-4
-
- There are more pages in this discussion • 286 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $135 | 45K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
51 | 92218918 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 76402411 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
51 | 92218918 | 0.002 |
18 | 77595009 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 76402411 | 24 |
0.004 | 17087707 | 16 |
0.005 | 22033532 | 10 |
0.006 | 19255067 | 9 |
0.007 | 5722471 | 6 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |